Skip to content
Clinical Trials – home
LuxembourgBack to Luxembourg

Clinical trials in Libramont-Chevigny – page 3

46 clinical trials in Libramont-Chevigny, Luxembourg. Every trial is listed in the EU Clinical Trials Register and updated daily.

Libramont-Chevigny at a glance
46
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

46 trials in Libramont-Chevigny

Open in trial search

Study Comparing Datopotamab Deruxtecan and Docetaxel for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Daiichi Sankyo Inc.

Study on the Safety and Effectiveness of IMGN151 for Women with Recurrent Endometrial and Ovarian Cancer

Registered drugNo placebo
Countries:LuxembourgLuxembourg
  • Participants:18–64 years · 65+ years
  • Substances:Brimonidine Tartrate
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Endometrial cancer

Not recruiting

Study on Durvalumab, Paclitaxel, Carboplatin, and Olaparib for Patients with Advanced or Recurrent Endometrial Cancer

Registered drug
Countries:LuxembourgLuxembourg
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Study of Nous-209 Genetic Vaccine and Pembrolizumab for Patients with Advanced Microsatellite Instability-High Colorectal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:GAD20-209-FSP-A1
  • Sponsor:Nouscom S.r.l.

Title: Study of everolimus with hormone therapy in women with high-risk breast cancer (ER-positive, HER2-negative) who are disease-free after initial treatment

Registered drug
Countries:LuxembourgLuxembourg
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Unicancer

Breast cancer

Not recruiting

Study on the Effects and Safety of Camizestrant (AZD9833) Compared to Fulvestrant in Postmenopausal Women with Advanced ER-Positive HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:LuxembourgLuxembourg
  • Participants:18–64 years · 65+ years
  • Substances:Camizestrant
  • Sponsor:AstraZeneca AB

Breast cancer female

Not recruiting

Study on Chemotherapy and Hormone Therapy for Women Over 70 with ER-Positive, HER2-Negative Breast Cancer Using Cyclophosphamide and Drug Combination

Registered drugNo placebo
Countries:LuxembourgLuxembourg
  • Participants:65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Unicancer

Neoplasm

Not recruiting

Study on DF1001, Nivolumab, and Paclitaxel for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:LuxembourgLuxembourg
  • Participants:18–64 years · 65+ years
  • Substances:DF1001
  • Sponsor:Dragonfly Therapeutics Inc.

Atrial fibrillation+2

Not recruiting

Study on Long-Term Anticoagulation with Rivaroxaban vs. Acetylsalicylic Acid for Patients at Risk of Stroke After Atrial Fibrillation Ablation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:University Of Ottawa Heart Institute

Study of SBP-101, Nab-Paclitaxel, and Gemcitabine for Patients with Metastatic Pancreatic Cancer

Registered drug
Countries:LuxembourgLuxembourg
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Panbela Therapeutics Inc.

Study Comparing Ceralasertib and Durvalumab with Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo
Countries:LuxembourgLuxembourg
  • Participants:18–64 years · 65+ years
  • Substances:Ceralasertib
  • Sponsor:AstraZeneca AB

Gastric cancer

Not recruiting

Study of Bemarituzumab with Chemotherapy and Nivolumab in Untreated Advanced Gastric and Gastroesophageal Junction Cancer Patients with FGFR2b Overexpression

Registered drug
Countries:LuxembourgLuxembourg
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Other cities in Luxembourg

The busiest research cities in the country

All 2 cities in Luxembourg

Clinical research in Libramont-Chevigny

What the registry says about research in the country

01 Breast Cancer Research

Multiple clinical trials focusing on advanced breast cancer treatments, particularly for patients with different receptor statuses including HER2-negative and hormone receptor-positive cases. Studies evaluate novel therapeutic combinations and treatment approaches.

  • Hormone receptor-positive treatments
  • Triple-negative breast cancer therapies
  • Combination therapy approaches
02 Lung Cancer Studies

Innovative research exploring non-small cell lung cancer treatments and new therapeutic options for extensive-stage small cell lung cancer. Trials evaluate various treatment combinations and compare effectiveness with standard therapies.

  • Advanced NSCLC treatments
  • Immunotherapy combinations
  • Novel therapeutic approaches
03 Gynecological Oncology

Comprehensive studies investigating treatments for various gynecological cancers, including endometrial, ovarian, and fallopian tube cancers. Research focuses on combining immunotherapy with standard treatments.

  • Endometrial cancer therapies
  • Ovarian cancer treatments
  • Advanced peritoneal cancer approaches
04 Urological Cancer Research

Clinical trials examining new treatments for bladder cancer and prostate cancer, including studies of innovative therapeutic combinations and maintenance therapies.

  • Non-muscle invasive bladder cancer
  • Metastatic prostate cancer
  • Novel combination approaches
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.